WOCKPHARMA

Analyst & Market Outlook Technical momentum: Wockhardt has seen a sharp rally recently—up ~45% in a month—driven by strong trading volume and optimism around its new antibiotic “Zaynich,” pending approval and aiming at a US$7 billion market . undamentals & Risks Revenue & profitability: The company posted a narrowed loss in Q4 FY25, with revenue climbing. However, its trailing-twelve-month (TTM) profit remains negative (~₹57 Cr loss) . Debt levels: Net debt rose to ~₹1,668 Cr as of Mar‑2025 (from ~₹1,054 Cr a year earlier), which raises concerns on interest coverage .